Table 1 Clinical characteristics of 194 participants in this study. There is a significant increase in parameters related to T2DM which confirms the state of disease and health of control group
From: Serum concentration of asprosin in new-onset type 2 diabetes
Parameter | Control | T2DM | P-value |
|---|---|---|---|
N | 97 | 97 | – |
Sex (M/F) | 50/47 | 50/47 | – |
Age (year)# | 52 (10) | 54 (7) | 0.290 |
BMI (kg/m2)# | 26.66 (3.01) | 27 (3.27) | 0.272 |
FBG (mg/dL)# | 88.5 (15.0) | 150 (69) | < 0.001 |
HbA1c (%)# | 5.2 (0.6) | 7.3 (1.92) | < 0.001 |
Insulin (mIU/L)# | 5.35 (4.13) | 11.77 (5.3) | < 0.001 |
HOMA-IR# | 0.68 (0.51) | 1.79 (0.75) | < 0.001 |
HOMA-β# | 80.55 (39.15) | 38.90 (41.20) | < 0.001 |
HOMA-S# | 145.9 (108.02) | 55.10 (24.50) | < 0.001 |
QUICKI# | 0.38 (0.04) | 0.30 (.03) | < 0.001 |
TC (mg/dL)* | 197.21 ± 39.1 | 193.75 ± 43.51 | 0.72 |
TAG (mg/dL)# | 137.50 (66) | 182 (151) | < 0.001 |
HDL-C (mg/dL)# | 54 (16) | 40 (8) | < 0.001 |
LDL-C (mg/dL)# | 96 (27) | 143 (43) | < 0.001 |
LDL-C/HDL-C# | 1.96 (0.54) | 3.57 (1.00) | < 0.001 |
TC/HDL-C# | 3.75 (0.87) | 4.84 (1.39) | < 0.001 |
TAG/HDL-C# | 3.56 (1.72) | 3.88 (2.45) | 0.626 |
Asprosin (ng/mL)* | 3.50 (1.85) | 4.18 (4.4) | < 0.001 |